Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308463822> ?p ?o ?g. }
- W4308463822 endingPage "573.e11" @default.
- W4308463822 startingPage "573.e1" @default.
- W4308463822 abstract "Hypertension complicates 2% to 8% of all pregnancies and is a leading cause of maternal and perinatal morbidity and mortality globally. Given the prognostic role that angiogenic markers play in evaluation of patients with suspected preeclampsia, the International Society for the Study of Hypertension in Pregnancy incorporated angiogenic imbalance into the 2021 definition of preeclampsia. As women with suspected preeclampsia are a heterogeneous group, with some already meeting the diagnostic criteria for preeclampsia, we evaluated whether the soluble fms-like tyrosine kinase-1/placental growth factor ratio adds prognostic value among these women.This study aimed to assess the additive value of soluble fms-like tyrosine kinase-1/placental growth factor ratio when the diagnostic criteria for preeclampsia have already been met.This was a secondary analysis of a prospective cohort study of patients presenting to obstetrical triage with suspected preeclampsia at ≥20+0 weeks' gestation from July 2009 to June 2012 in Boston, United States. Clinicians were masked to soluble fms-like tyrosine kinase-1/placental growth factor ratio results. Clinical records were reviewed for maternal and neonatal care and outcomes. The value of the soluble fms-like tyrosine kinase-1/placental growth factor ratio (≤38, >38, or >85) was assessed for identifying women at low or high risk of evolving into preeclampsia with severe features within 2 weeks of the triage visit, with preeclampsia with severe features being defined by the American College of Obstetricians and Gynecologists (2013 definition). Based on information in obstetrical triage, preeclampsia among triage patients was defined either by: (1) The International Society for the Study of Hypertension in Pregnancy restrictive criteria (ie, new-onset hypertension and proteinuria at ≥20 weeks), or (2) The International Society for the Study of Hypertension in Pregnancy broad maternal criteria (ie, new-onset hypertension with proteinuria or one/more relevant maternal end-organ complications).Of 1043 patients included, 459 presented at 20+0 to 34+6 weeks and 584 at ≥35+0 weeks. In triage, 25.8% of women with suspected preeclampsia already met the preeclampsia criteria based on the International Society for the Study of Hypertension in Pregnancy broad criteria and 22.0% based on the restrictive criteria. In separate multivariable analyses adjusted for gestational age, a soluble fms-like tyrosine kinase-1/placental growth factor ratio >38 was independently associated with preeclampsia with severe features within 2 weeks even after adjusting for preeclampsia diagnosis in obstetrical triage, whether that preeclampsia were defined restrictively (odds ratio, 15.62; 95% confidence interval, 8.91-27.40) or broadly (odds ratio, 14.56; 95% confidence interval, 8.30-25.56). A soluble fms-like tyrosine kinase-1/placental growth factor ratio ≤38 was good at ruling out development of preeclampsia with severe features within 2 weeks among all patients and among those meeting the restrictive or broad definitions of preeclampsia (negative likelihood ratios, ≤0.16), driven by performance of the ratio before 35 weeks (ie, negative likelihood ratio ≤0.12). A soluble fms-like tyrosine kinase-1/placental growth factor ratio >85 was good at ruling-in preeclampsia with severe features within 2 weeks among women with suspected preeclampsia, either before (positive likelihood ratio, 8.20) or after 35 weeks (positive likelihood ratio, 6.00) and fair at ruling-in preeclampsia with severe features within 2 weeks when preeclampsia had already been confirmed in patients at <35 weeks (restrictively positive likelihood ratio, 3.48, or broadly positive likelihood ratio, 3.40).Our findings support the prognostic value of the soluble fms-like tyrosine kinase-1/placental growth factor ratio among patients with confirmed preeclampsia, particularly to identify those both likely and unlikely to progress toward the development of severe features in the next 2 weeks and those who may be most appropriate for expectant and potentially outpatient care. Our findings support the incorporation of angiogenic imbalance into the definition of preeclampsia, particularly at 20-34+0 weeks." @default.
- W4308463822 created "2022-11-12" @default.
- W4308463822 creator A5005723596 @default.
- W4308463822 creator A5013343091 @default.
- W4308463822 creator A5030601893 @default.
- W4308463822 creator A5051045029 @default.
- W4308463822 creator A5060277637 @default.
- W4308463822 creator A5071802691 @default.
- W4308463822 creator A5072854510 @default.
- W4308463822 creator A5077769927 @default.
- W4308463822 creator A5087807797 @default.
- W4308463822 date "2023-05-01" @default.
- W4308463822 modified "2023-10-01" @default.
- W4308463822 title "The additive role of angiogenic markers for women with confirmed preeclampsia" @default.
- W4308463822 cites W1990795537 @default.
- W4308463822 cites W1997689449 @default.
- W4308463822 cites W2005042579 @default.
- W4308463822 cites W2006245385 @default.
- W4308463822 cites W2017460912 @default.
- W4308463822 cites W2061506872 @default.
- W4308463822 cites W2065594976 @default.
- W4308463822 cites W2134502189 @default.
- W4308463822 cites W2143180984 @default.
- W4308463822 cites W2145917688 @default.
- W4308463822 cites W215906235 @default.
- W4308463822 cites W2161934818 @default.
- W4308463822 cites W2168757245 @default.
- W4308463822 cites W2233974801 @default.
- W4308463822 cites W2518766442 @default.
- W4308463822 cites W2804779046 @default.
- W4308463822 cites W2930104874 @default.
- W4308463822 cites W2971567043 @default.
- W4308463822 cites W3080046451 @default.
- W4308463822 cites W3094227856 @default.
- W4308463822 cites W3096349226 @default.
- W4308463822 cites W3108569584 @default.
- W4308463822 cites W3109973303 @default.
- W4308463822 cites W3112331226 @default.
- W4308463822 cites W3112552530 @default.
- W4308463822 cites W3207420069 @default.
- W4308463822 cites W4200606351 @default.
- W4308463822 cites W4205820712 @default.
- W4308463822 cites W4226033627 @default.
- W4308463822 cites W4236182870 @default.
- W4308463822 doi "https://doi.org/10.1016/j.ajog.2022.10.044" @default.
- W4308463822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36356699" @default.
- W4308463822 hasPublicationYear "2023" @default.
- W4308463822 type Work @default.
- W4308463822 citedByCount "1" @default.
- W4308463822 countsByYear W43084638222023 @default.
- W4308463822 crossrefType "journal-article" @default.
- W4308463822 hasAuthorship W4308463822A5005723596 @default.
- W4308463822 hasAuthorship W4308463822A5013343091 @default.
- W4308463822 hasAuthorship W4308463822A5030601893 @default.
- W4308463822 hasAuthorship W4308463822A5051045029 @default.
- W4308463822 hasAuthorship W4308463822A5060277637 @default.
- W4308463822 hasAuthorship W4308463822A5071802691 @default.
- W4308463822 hasAuthorship W4308463822A5072854510 @default.
- W4308463822 hasAuthorship W4308463822A5077769927 @default.
- W4308463822 hasAuthorship W4308463822A5087807797 @default.
- W4308463822 hasConcept C126322002 @default.
- W4308463822 hasConcept C131872663 @default.
- W4308463822 hasConcept C167734588 @default.
- W4308463822 hasConcept C188816634 @default.
- W4308463822 hasConcept C194828623 @default.
- W4308463822 hasConcept C2776871010 @default.
- W4308463822 hasConcept C2777025900 @default.
- W4308463822 hasConcept C2777120189 @default.
- W4308463822 hasConcept C2777218350 @default.
- W4308463822 hasConcept C2779184299 @default.
- W4308463822 hasConcept C2779234561 @default.
- W4308463822 hasConcept C29456083 @default.
- W4308463822 hasConcept C46973012 @default.
- W4308463822 hasConcept C54355233 @default.
- W4308463822 hasConcept C71924100 @default.
- W4308463822 hasConcept C86803240 @default.
- W4308463822 hasConceptScore W4308463822C126322002 @default.
- W4308463822 hasConceptScore W4308463822C131872663 @default.
- W4308463822 hasConceptScore W4308463822C167734588 @default.
- W4308463822 hasConceptScore W4308463822C188816634 @default.
- W4308463822 hasConceptScore W4308463822C194828623 @default.
- W4308463822 hasConceptScore W4308463822C2776871010 @default.
- W4308463822 hasConceptScore W4308463822C2777025900 @default.
- W4308463822 hasConceptScore W4308463822C2777120189 @default.
- W4308463822 hasConceptScore W4308463822C2777218350 @default.
- W4308463822 hasConceptScore W4308463822C2779184299 @default.
- W4308463822 hasConceptScore W4308463822C2779234561 @default.
- W4308463822 hasConceptScore W4308463822C29456083 @default.
- W4308463822 hasConceptScore W4308463822C46973012 @default.
- W4308463822 hasConceptScore W4308463822C54355233 @default.
- W4308463822 hasConceptScore W4308463822C71924100 @default.
- W4308463822 hasConceptScore W4308463822C86803240 @default.
- W4308463822 hasFunder F4320307187 @default.
- W4308463822 hasFunder F4320307779 @default.
- W4308463822 hasFunder F4320322923 @default.
- W4308463822 hasIssue "5" @default.
- W4308463822 hasLocation W43084638221 @default.
- W4308463822 hasLocation W43084638222 @default.